



## ADULT MEDICATION GUIDELINE

# Cefazolin

<b>Scope (Staff):</b>	All WNHS Staff
<b>Scope (Area):</b>	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

### Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

### Restrictions

[Formulary: Unrestricted](#)

### Medication Class

Anti-infective – Cephalosporin

### Presentation

**Vial:** 1g, 2g

### Storage

Store at room temperature, below 25°C. Protect from light.

### Dose

Refer to KEMH Clinical Practice Guidelines: O&G:

#### **Surgical prophylaxis**

[Infection: Antibiotic Prophylaxis for Caesarean Section](#)

[Infections: Antibiotic Prophylaxis for Gynaecological and Urogynaecological Surgery](#)

#### **Intrapartum Group B Streptococcus prophylaxis (non-severe penicillin hypersensitivity):**

[Group B Streptococcal Disease](#)

---

**Prophylaxis for operative vaginal delivery (non-severe penicillin hypersensitivity)**

[Operative Vaginal Birth \(previously called 'Instrumental Vaginal Delivery'\)](#)

**Perineal care and repair**

[Perineal Care and Repair: Protection, Assessment and Management \(includes episiotomy, infiltration, suturing, third/fourth degree tears\)](#)

**Mastitis and breast abscess**

[Breastfeeding Challenges: Mastitis and Breast Abscess Management](#)

**Severe postpartum endometritis**

[Infections in Obstetrics \(Intra-amniotic Chorioamnionitis and Postpartum Infection\): Diagnosis and Management](#)

**Other**

[Endorsed Midwives Prescribing](#)

**Group A Streptococcus Infection**

[Group A Streptococcus \(GAS\)](#)

## Administration

Refer to the [Australian Injectable Drugs Handbook](#)

## Monitoring

Monitor renal function and complete blood count during prolonged (>10 days) and/or high-dose treatment

## Pregnancy

**1<sup>st</sup> Trimester:** Safe to use

---

**2<sup>nd</sup> Trimester:** Safe to use

**3<sup>rd</sup> Trimester:** Safe to use

## Breastfeeding

Safe to use

(May cause loose bowel actions in breastfed neonates or babies)

## Comments

- Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins.
- Dose reduction may be needed in renal impairment, risk of neurotoxicity with high doses; and risk of neutropenia may be increased.

## Australian Commission on Safety and Quality in HealthCare Standards:

[ACSQHC Standards>The NSQHS Standards>Preventing and Controlling Infections Standard>Antimicrobial Stewardship](#)

## WNHS Policy:

[Antimicrobial Stewardship](#)

## WNHS Pharmaceutical and Medicines Management Guidelines:

[Medication Management Framework](#)

## References

Australian Medicines Handbook. Cefazolin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2023 [cited 2023 June 27]. Available from: <https://amhonline.amh.net.au/>

Society of Hospital Pharmacists of Australia. Cefazolin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2023 [cited 2023 June 27]. Available from: <http://aidh.hcn.com.au>

Keywords	Cefazolin, mastitis, caesarean section, surgical prophylaxis, gynaecological prophylaxis, cephalosporin, GBS, Group B Streptococcus, group A strep				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	V4				
Date First Issued:	Jan 2015	Last Reviewed:	Jun 2023	Review Date:	Jun 2028
Endorsed by:	Medicines and Therapeutics Committee			Date:	06/02/2024
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.            Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2024

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.